Multi-geography CEO — Healthcare · anchored Singapore

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Healthcare & Life Sciences on a senior CEO leadership mandate anchored in Singapore. The remit explicitly spans USA.

This is a multi-geography leadership role requiring orchestration across time zones, matrix stakeholders, and often dual-reporting into global and regional lines.

The organisation is looking for pattern recognition: someone who has seen similar complexity before and knows which levers matter first.

Context you will inherit

• Market & sector: Managing the talent pipeline of clinically trained managers (MDs with MBAs, nursing administrators) who are chronically scarce in India
• Geographic spine: Primary hub Singapore with explicit corridor responsibility across USA.
• Organisation stage: Recent leadership turnover created ambiguity on priorities; you will need to re-establish a crisp enterprise storyline.
• Stakeholders: Key interfaces include headquarters strategy, regional risk and legal, local regulators (where material), and anchor channel partners.
• Secondary lens: ESG and social impact reporting — particularly for health systems receiving PE backing with ESG mandates

The mandate (12–24 month arc)

1. Growth vs. control: Set explicit appetite for risk-taking in new markets or products — and enforce it when teams overshoot.
2. Customer concentration: Diversify revenue where a handful of accounts dominate; deepen relationships without dependency blind spots.
3. JV / alliance health: Rationalise partnerships that drain management time; renegotiate or exit where economics no longer work.
4. Cost structure: Deliver productivity without hollow cuts — protect customer-facing capacity and critical controls.
5. Next-gen leadership: Identify and sponsor high-potential GMs earlier; reduce reliance on a few heroic executives.
6. Narrative to markets: Align external messaging with internal reality — especially during turnaround or repositioning phases.

Responsibilities (representative)

• Reset performance standards for the leadership population; act quickly on chronic underperformance.
• Align global programmes with local market reality — avoid copy-paste transformation.
• Represent the enterprise to investors, lenders, or PE partners with conservative, credible forecasts.
• Drive inclusion in succession and promotion decisions — measurable outcomes, not statements.
• Balance short-term recovery actions with investments that compound over three to five years.

Leadership profile

• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Communication: Executive presence in English; additional languages valued where market-relevant.
• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Strategic judgment: Evidence of clear portfolio choices — what to scale, fix, or exit — in Healthcare & Life Sciences.
• Geographic muscle: Comfort operating from Singapore with regular engagement across USA.

Team & culture

You inherit a mixed-tenure team — pockets of excellence beside roles that need upgrade. The mandate is to raise the bar without demoralising the organisation: clear standards, fair process, and visible wins that prove the new pace is achievable.

Success measures (examples)

• Financial: Revenue and margin vs. plan; cash conversion; capital efficiency.
• Strategic: Share in priority segments; customer retention in anchor accounts; milestone delivery on transformation.
• People: Engagement trends; regrettable attrition in critical roles; diversity of succession slate.
• Risk: Audit and regulatory outcomes; conduct events; operational resilience metrics.

First 90 days (orientation arc)

• Days 1–30: Shadow key customer journeys or operations — paper over slides where reality diverges.
• Days 30–60: Cut or pause low-value projects freeing capacity for strategic work.
• Days 60–90: Publish first integrated forecast or plan under your ownership — even if directional.
• Build trust with risk, legal, and audit through transparency — surprises erode licence to move fast.
• Pick one cultural signal (e.g. meeting hygiene, promotion criteria) and model it relentlessly.
• Clarify RACI for cross-border deals, staffing, and pricing exceptions.

Stakeholder map (illustrative)

• Internal: Matrix of global product houses and local P&L; tension is normal — your role is to broker trade-offs with data.
• External: Customers who influence reference deals; government or industry bodies in regulated sectors.
• Capital providers: Banks, sponsors, or minority investors — each needs a slightly different narrative on risk.

Travel & mobility

Multi-hub rhythm — plan for weekly or bi-weekly cross-border travel during integration or transformation peaks.

Compensation

Competitive CEO compensation for Healthcare & Life Sciences leadership: cash, incentive, benefits, and potential equity or carry (case-dependent). Discussed with finalists only.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Healthcare & Life Sciences and Singapore. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: healthcare-life-sciences · CEO · Singapore · Gladwin International Leadership Advisors